Navigating α-Synuclein Aggregation Inhibition: Methods, Mechanisms, and Molecular Targets

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Parkinson's disease (PD) is an incurable, age-related neurodegenerative disorder.
• A hallmark of PD is the aggregation of the neuronal protein alpha-synuclein (α-synuclein) into amyloid fibrils.
• Inhibiting α-synuclein aggregation is a promising therapeutic strategy for PD.

Purpose of the Study:

• To provide a comprehensive overview of inhibitors targeting α-synuclein fibrillization.
• To critically analyze the mechanisms of action and specificity of various inhibitors.
• To compare different strategies for targeting various α-synuclein species.

Main Methods:

• Literature review of small molecule, peptide, and protein inhibitors of α-synuclein fibrillization.
• Analysis of inhibitor specificity and action mechanisms, including polyphenol oxidation and α-synuclein cross-linking.
• Comparison of approaches targeting monomeric, oligomeric, and fibrillar α-synuclein.

Main Results:

• Various classes of inhibitors (small molecules, peptides, proteins) have been reported.
• Inhibitor efficacy is linked to specificity and mechanisms like polyphenol oxidation and cross-linking.
• Strategies targeting different α-synuclein species have distinct advantages and disadvantages.

Conclusions:

• Developing disease-modifying treatments for Parkinson's disease requires a deep understanding of α-synuclein aggregation inhibitors.
• Critical analysis of inhibitor mechanisms and specificity is crucial for therapeutic development.
• Further research is needed to optimize strategies for targeting α-synuclein species and testing inhibitor efficacy.